What Eleison Pharmaceuticals does

Eleison Pharmaceuticals is a private, clinical-stage pharmaceutical company founded in 2009 and based in Princeton, New Jersey. The company acquires, develops, and commercializes clinical-stage drug candidates focused on oncology, with its lead asset being glufosfamide, an investigational chemotherapeutic agent that has completed Phase 3 clinical trials for the treatment of pancreatic cancer. As glufosfamide is not yet FDA-approved and no commercial product exists, the company is pre-revenue and operates with a small team of 1–10 employees. Its stated business model is to license or commercialize drug candidates through standard pharmaceutical channels upon regulatory clearance.

The company has no in-house AI infrastructure. Instead, it partnered with BullFrog AI to apply the bfLEAP causal AI platform to its Phase 3 glufosfamide data, and with Moffitt Cancer Center for clinical research collaboration. This combined effort applied data-driven clustering and causal analysis to identify biomarker-defined patient subgroups showing nearly threefold improvement in overall survival, reframing glufosfamide as a candidate for personalized oncology rather than a broad chemotherapy. The findings were accepted for presentation at the 2026 ASCO GI Symposium, providing third-party scientific validation of the biomarker work.

Eleison's primary end market is pancreatic cancer patients, with a secondary engagement targeting oncology drug developers through collaborative research. Its go-to-market strategy relies on traditional pharmaceutical commercialization pathways post-approval, supported by scientific dissemination via peer-reviewed publications and medical conference presentations rather than direct consumer or B2B marketing. No pricing, revenue model, or commercial channel data is disclosed, consistent with its pre-commercial clinical status.

Name

Eleison Pharmaceuticals

Website

https://eleison-pharma.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

1–10 employees

Short description

Eleison Pharmaceuticals is a private, clinical-stage pharmaceutical company founded in 2009 that acquires, develops, and commercializes oncology drug candidates, with its lead asset glufosfamide in Phase 3 trials for pancreatic cancer.

Ownership category

akta.pro rank

Product category

Oncology Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

Keywords

• Clinical-stage oncology drug development
• Pancreatic cancer therapeutics
• Investigational chemotherapy agents
• Repurposed oncology drugs
• Biomarker-driven patient stratification

Headquarters

HQ city

Princeton

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Marketing or Sales

Core offering

Eleison Pharmaceuticals is a clinical-stage biopharmaceutical company that acquires, develops, and plans to commercialize drug candidates for cancer patients. Its lead asset, glufosfamide, is an investigational chemotherapeutic agent being evaluated for the treatment of pancreatic cancer. The company pairs late-stage drug development with AI-driven biomarker analytics to enable personalized oncology treatment strategies.

Product overview

Eleison Pharmaceuticals is a pharmaceutical company focused on drug development for cancer treatments. Based on the available sources, the company's pipeline includes glufosfamide, an investigational chemotherapeutic agent developed for pancreatic cancer treatment. The company has conducted phase 3 clinical trials for this drug candidate. The company collaborates with technology partners like BullFrog AI for AI-driven analysis of clinical trial data to identify biomarkers and refine patient stratification for personalized oncology treatment strategies.

Differentiator

Problem solved

Functional benefit

Products and services

• Glufosfamide An investigational chemotherapeutic agent being developed by Eleison Pharmaceuticals for the treatment of pancreatic cancer. Phase 3 clinical trial data was analyzed using causal AI to identify patient subtypes with enhanced treatment response and improved overall survival, supporting biomarker-guided personalized oncology treatment strategies.

Quantifiable outcome

• Nearly threefold improvement in overall survival for biomarker-identified patient subgroups in pancreatic cancer trial
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature1 record

Partnerships

Two partnerships are on record, tiered core.

• BullFrog AIcoreStrategic or Co-development Partner · 9 January 2026BullFrog AI's bfLEAP® causal AI platform analyzed Eleison Pharmaceuticals' Phase 3 pancreatic cancer clinical trial data for glufosfamide. The collaboration identified key biomarkers and patient subgroups showing nearly threefold improvement in overall survival. Findings were accepted for presentation at the 2026 ASCO GI Symposium. The partnership enables data-driven patient stratification and personalized treatment strategies.
• Moffitt Cancer CentercoreStrategic or Co-development Partner · 9 January 2026Moffitt Cancer Center collaborated with Eleison Pharmaceuticals and BullFrog AI on the analysis of pancreatic cancer clinical trial data. The research partnership focused on using AI to identify patient subtypes responsive to glufosfamide for personalized cancer treatment strategies. Findings were presented at the 2026 ASCO GI Symposium.

Recent moves4 records

Expansion highlights3 records

Direct peers

• Rafael Pharmaceuticals: Rafael Pharmaceuticals previously developed glufosfamide and is a closely aligned clinical-stage oncology company in the same pancreatic cancer space, providing the most direct asset-level comparison for Eleison.
• ImmunityBio: ImmunityBio is a clinical-stage oncology company with active pancreatic cancer programs, making it a direct therapeutic-area peer even though its modality (immunotherapy) differs from glufosfamide's chemotherapy approach.

Emerging players

• BullFrog AI: BullFrog AI's bfLEAP causal AI platform is the analytical engine behind Eleison's biomarker findings. While not a drug developer, it is the closest technology and operating partner and exemplifies AI-enabled clinical repositioning peers.
• Lantern Pharma: Lantern Pharma uses AI and genomics to reposition and develop precision oncology drug candidates, sharing Eleison's model of leveraging computational platforms to advance clinical-stage cancer assets in niche indications.
• Recursion Pharmaceuticals: Recursion applies high-throughput biology and AI-driven drug discovery to oncology and rare diseases, representing a scaled, publicly traded peer using computational methods to accelerate clinical-stage oncology pipelines.
• Exscientia: Exscientia is an AI-driven precision medicine company developing clinical-stage oncology assets, comparable to Eleison in its use of AI tooling to advance small-molecule drug candidates into the clinic.
• Berg Health: Berg Health applies AI-driven biology to discover and develop oncology and rare disease therapeutics, sharing Eleison's positioning as a small, AI-enabled clinical-stage oncology developer.

Broad incumbents

• Schrödinger, Inc. Schrödinger provides computational chemistry and AI-based drug design platforms used by multiple pharma developers, and operates its own clinical-stage oncology collaborations, making it a broad incumbent peer in AI-enabled drug development.
• Tempus AI: Tempus AI builds oncology-focused data and AI infrastructure for clinical and translational workflows, including biomarker identification similar in spirit to the bfLEAP analyses Eleison used to identify glufosfamide responders.
• FibroGen: FibroGen is a small-cap clinical-stage biopharma with a similarly lean operational footprint developing therapeutics in oncology-adjacent specialty indications, providing a size and stage-comparable public peer benchmark.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat3 records

Key risks4 records

Key highlights4 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eleison Pharmaceuticals